Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer

11 Feb 2022

Abstract excerpt

BACKGROUND: Tumor recurrence and progression in non-muscle invasive bladder cancer (NMIBC), therapy failure, and severe side effects in muscle invasive bladder cancer (MIBC) are the major challenges in the clinical management of bladder cancer (BC). Here, we identify new molecular targetable signatures to improve BC patients' stratification and the outcome of current immunotherapies. MATERIAL AND METHODS: In a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Immunotherapy and Biomarkers
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35223454
DOI: 10.3389/fonc.2021.795242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder CancerPMID 35223454Read ↗

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets MeetSemantic proximity Read ↗

miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay – A reviewSemantic proximity Read ↗

Identification of RB1 Gene as a Immune-Related Prognostic Signature Based on Tumor Mutation Burdens in Bladder CancerSemantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

Correlation between the immune microenvironment and bladder cancer based on a prognostic miRNA risk modelSemantic proximity Read ↗

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Semantic proximity Read ↗

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypesSemantic proximity Read ↗

Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.Semantic proximity Read ↗

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity Read ↗

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.Semantic proximity Read ↗

Molecular targets and targeted therapies in bladder cancer managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.